Adjuvant topical dorzolamide or timolol with intravitreal bevacizumab for diabetic macular edema: A double-blind randomized controlled trial
Diabetic macular edema (DME) is a leading cause of visual impairment among diabetic patients, primarily managed with intravitreal anti-VEGF agents such as bevacizumab. However, the exploration of adjunctive therapies to enhance treatment outcomes remains an area of ongoing research. This study inves...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Caspian Medical Futurology
2024-03-01
|
| Col·lecció: | Journal of Current Biomedical Reports |
| Matèries: | |
| Accés en línia: | https://jcbior.com/index.php/JCBioR/article/view/279 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|